As COVID-19 vaccine sales continue to soar, Moderna Chief Executive Stephane Bancel’s total personal financial compensation increased by 41 percent in 2021, reaching $18.2 million. The company’s total revenue rose 2,200 percent in 2021, jumping from $803 million to $18.5 billion.1 2 Moderna partnered with the National Institute of Allergy and Infectious Diseases (NIAID), headed […]
Pfizer CEO Albert Bourla, who recently announced that a fourth COVID-19 vaccine dose will be necessary for everyone who has already gotten three doses, was awarded $24.3 million in personal financial compensation in 2021. In addition to his $1.69 million salary, which increased by 15 percent, Bourla took home a cash incentive of $8 million, […]
For the last 27 years, I have been a professor at Boston College, teaching a mix of literature and writing courses to thousands of students. Then along came the booster mandates. When the initial vaccines came out, my wife and I received ours. We had strong reservations about the mRNA vaccines and had decided we […]
“If only there were a message that could break through skepticism and persuade unvaccinated people to get their shots. What a world that would be. But over the past year, this really did happen,” reads a February 2022 Vox article1 that continues on to describe a Harvard Business School publication2 which offers new evidence on […]
Based on better than expected sales of its experimental messenger RNA (mRNA) BNT162b2 COVID-19 biologic, New York-based pharmaceutical company Pfizer, Inc. last summer revised projected sales of its experimental drug, also known as “Comirnaty,” from $26 billion to $33.5 billion in 2021. Characterizing second-quarter sales of BNT162b2 as “remarkable,” Pfizer’s chief executive officer (CEO) Albert […]
On Dec. 1, 2021, the first case of the new SARS-CoV-2 variant known as Omicron (initially designated “B.1.1.529”) in the United States was confirmed by the U.S. Centers for Disease Control and Prevention (CDC) in California. The case involves a fully vaccinated individual in San Francisco who had returned from a trip to South Africa […]
In an interview with CNBC on Dec. 8, 2021, Pfizer CEO Albert Bourla said that he expects sooner rather than later all Americans will have to get a fourth dose of Pfizer/BioNTech’s experimental messenger RNA (mRNA) BNT162b2 biologic for COVID-19 to try to protect against the Omicron variant of the SARS-CoV-2 virus causing mostly mild COVID disease. […]
As part of an effort to reopen their borders and encourage travelers from outside of Europe, the 27 member states of the European Union (E.U.) began issuing an “E.U. Digital COVID Certificate” (EUDCC) on July 1, 2021 to people who have receive COVID vaccinations to allow freedom of movement within the region. The travel scheme, […]
On Oct. 20, 2021, the Biden administration outlined plans to begin giving COVID-19 vaccinations to children between five and 11 years old. Pending the results of reviews of the plan by the U.S. Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) over the […]
Pfizer, Inc. reported that the company sold $7.8 billion worth of their COVID-19 biologic BNT162b2 in the second quarter of this year raising the company’s 2021 sales forecast for the two-dose vaccine to $33.5 billion from the previously estimated $26 billion.1 The $7.8 billion from direct sales of the shot is split with its German […]